IDH1 mutation

The interpretability of distance-based subcortical motor mapping is influenced by IDH1 mutation status, whereas continuous CUSA stimulation and ball-tip stimulation show comparable overall distance-threshold behavior. Distance-based scMEP thresholds are more reliable in IDH1-mutant tumors, whereas increased variability in IDH1-wildtype tumors likely reflects greater susceptibility to intraoperative brain shift and other biological factors, supporting a biologically informed, real-time electrophysiological approach in motor-eloquent tumor resections.

IDH1-vac-induced T cell responses were detected in the inflamed brain lesion of an IDH1-vac-associated pseudoprogression, whereas no IDH1-vac-induced T cells were found in participants with early progressive disease. The favorable long-term outcome of the NOA16 cohort supports investigating IDH1-vac in persons with newly diagnosed grade 3 and 4 (World Health Organization classification 2021) IDH-mutant astrocytomas in a randomized phase 2 trial (ClinicalTrials.gov identifier: NCT02454634 ).

These findings highlight the heterogeneity of immune cell infiltration in tumors and its impact on patient prognosis and treatment sensitivity. The findings suggest that immune subtypes can serve as valuable biomarkers, particularly IDH1 mutations in cold tumors, paving the way for personalized cancer therapies.

Chemoimmunotherapy is the reference first-line regimen for biomarker-unselected advanced cholangiocarcinoma. Early comprehensive genomic profiling is essential to enable timely, matched targeted therapy and maximize population-level benefit.

This review synthesizes current evidence on the roles of IDH1/2 mutations and dysregulation of AXL signaling in CS, emphasizing their potential contributions to tumor aggressiveness, immune suppression, and resistance to therapy. Additionally, we explore current developments in targeted therapy exploiting IDH1/2 and AXL dysregulation.

We evaluate the expanding clinical trial landscape of immunotherapy in CCA and more broadly in BTC, including adoptive cell therapies and cancer vaccines. Together, these advances position CCA as a paradigm of how tumor genotype and microenvironment co-evolve to define immunotherapy sensitivity and resistance.

P2, N=25, Recruiting, Timothy Pardee | Not yet recruiting --> Recruiting

In contrast, miR-340 was downregulated in glioma cells, and its direct transfection markedly inhibited proliferation without astrocyte toxicity; fluorescent miR-340 was also detected within TMs and recipient glioma cells. Together, these findings identify TMs as structural features shaped by IDH1 mutation and as conduits for intercellular exchange of both oncogenic and tumor-suppressive microRNAs, providing a framework for understanding TM-mediated communication and its potential therapeutic exploitation in glioma.

This case raises the possibility of an association between Maffucci syndrome and recurrent papillary breast lesions. In the absence of molecular confirmation, this relationship remains speculative and should be regarded as hypothesis generating, underscoring the need for further investigation with genetic and immunohistochemical correlation rather than changes to established breast cancer screening guidelines.

This selected real-world cohort demonstrates durable responses exceeding published benchmarks and has one of the longest follow-up periods reported for IDHi in AML. A subset of older adults with IDH-mutated AML can achieve highly durable remissions on IDHi without significant toxicity.

18F-FDG PET/CT shows limited sensitivity because of low glycolytic activity and physiologic uptake. This case highlights the superior performance of 18F-NaF PET/CT for osteoblastic lesion detection and anatomic delineation in a pediatric patient with IDH1-mutated Ollier disease.

P1, N=15, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Dec 2026